Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2 ‐year Results from the FUTURE 2 Study

ConclusionA greater proportion of patients achieved MDA with secukinumab versus placebo at Week 16, with response rates sustained through 2 years. MDA was associated with improved PROs, including QoL, through 2 years.This article is protected by copyright. All rights reserved.

Source: Arthritis Care and Research - February 1, 2018 Category: Rheumatology Authors: Laura C Coates, Philip J Mease, Laure Gossec, Bruce Kirkham, Bintu Sherif, Corine Gaillez, Shephard Mpofu, Steffen M Jugl, Chetan Karyekar, Kunal K Gandhi Tags: Brief Report Source Type: research